Overview
Compare with Adagio Medical Holdings, Inc., Bluejay Diagnostics, Inc. or PULSE BIOSCIENCES, INC., or pick any stock.
- TickerQTEX on Nasdaq1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersL31
- Incorporated inIsrael3
- Business addressHatidhar 2, 11Th Floor, Ra'Anana3
- Filer categoryNon-accelerated filer, Emerging growth company3
- Legal formCorporation
See how the biggest companies compare on our leaderboards
SEC as frequently or as promptly as U.S. domestic companies registered under the Exchange Act.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue4¢$287.0K
- Research and development96¢$7.5M
Out of $289.0K in revenue.2 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenues | $289.0K | $0 | $0 |
| Cost of revenues | $287.0K | $0 | $0 |
| Gross Profit | $2.0K | $0 | $0 |
| Research and development expenses | $7.5M | $6.3M | $7.3M |
| General and administrative expenses | $5.5M | $4.2M | $4.1M |
| Sales and marketing expenses | $588.0K | $754.0K | $746.0K |
| Other expenses | $9.0K | $5.0K | $4.0K |
| Operating loss | $13.6M | $11.3M | $12.1M |
| Interest income from deposits | -$64.0K | -$172.0K | -$318.0K |
| Finance expenses (income), net | -$339.0K | -$42.0K | -$529.0K |
| Loss before tax | $13.2M | $11.1M | $11.3M |
| Taxes on income | $0 | $0 | $0 |
| Total comprehensive and net loss | $13.2M | $11.1M | $11.3M |
| Net loss per ordinary share, basic (in Dollars per share) | -$0.45 | -$0.60 | -$0.93 |
| Net loss per ordinary share, diluted (in Dollars per share) | -$0.45 | -$0.60 | -$0.93 |
| Weighted average number of ordinary shares outstanding basic (in Shares) | 29.6M shares | 18.5M shares | 12.1M shares |
| Weighted average number of ordinary shares outstanding diluted (in Shares) | 29.6M shares | 18.5M shares | 12.1M shares |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $3.2M | $5.1M | $5.0M | |
| Deposits | $0 | $668.0K | ||
| Other current assets | $517.0K | $587.0K | ||
| Inventory | $735.0K | $444.0K | ||
| Total current assets | $4.4M | $6.8M | ||
| Right of use assets, net | $478.0K | $761.0K | ||
| Property, plant and equipment, net | $452.0K | $499.0K | ||
| Total non-current assets | $930.0K | $1.3M | ||
| Total Assets | $5.3M | $8.1M | ||
| Trade accounts payables | $107.0K | $154.0K | ||
| Other accounts payables | $1.3M | $1.4M | ||
| Lease liabilities | $286.0K | $277.0K | ||
| Financial liabilities at fair value | $1.1M | $1.6M | ||
| Total current liabilities | $2.8M | $3.4M | ||
| Lease liabilities | $194.0K | $378.0K | ||
| Total non- current liabilities | $194.0K | $378.0K | ||
| Ordinary shares, no par value: Authorized 100,000,000 ordinary shares as of December 31, 2025 and December 31, 2024; Issued and outstanding 35,949,247 ordinary shares as of December 31, 2025 and 24,252,096 shares as of December 31, 2024 | $0 | $0 | ||
| Share capital and additional paid in capital | $82.1M | $70.9M | ||
| Accumulated losses | -$79.8M | -$66.6M | ||
| Total Shareholders Equity | $2.3M | $4.3M | $5.7M | $13.6M |
| Total liabilities and Shareholders Equity | $5.3M | $8.1M | ||
| Ordinary shares, par value (in Dollars per share) | $0.00 | $0.00 | ||
| Ordinary shares, Authorized (in Shares) | 100.0M shares | 100.0M shares | ||
| Ordinary shares, Issued (in Shares) | 35.9M shares | 24.3M shares | ||
| Ordinary shares, Outstanding (in Shares) | 35.9M shares | 24.3M shares | 15.7M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $3.2M | $5.1M | $5.0M | |
| Deposits | $0 | $668.0K | ||
| Other current assets | $517.0K | $587.0K | ||
| Inventory | $735.0K | $444.0K | ||
| Total current assets | $4.4M | $6.8M | ||
| Right of use assets, net | $478.0K | $761.0K | ||
| Property, plant and equipment, net | $452.0K | $499.0K | ||
| Total non-current assets | $930.0K | $1.3M | ||
| Total Assets | $5.3M | $8.1M | ||
| Trade accounts payables | $107.0K | $154.0K | ||
| Other accounts payables | $1.3M | $1.4M | ||
| Lease liabilities | $286.0K | $277.0K | ||
| Financial liabilities at fair value | $1.1M | $1.6M | ||
| Total current liabilities | $2.8M | $3.4M | ||
| Lease liabilities | $194.0K | $378.0K | ||
| Total non- current liabilities | $194.0K | $378.0K | ||
| Ordinary shares, no par value: Authorized 100,000,000 ordinary shares as of December 31, 2025 and December 31, 2024; Issued and outstanding 35,949,247 ordinary shares as of December 31, 2025 and 24,252,096 shares as of December 31, 2024 | $0 | $0 | ||
| Share capital and additional paid in capital | $82.1M | $70.9M | ||
| Accumulated losses | -$79.8M | -$66.6M | ||
| Total Shareholders Equity | $2.3M | $4.3M | $5.7M | $13.6M |
| Total liabilities and Shareholders Equity | $5.3M | $8.1M | ||
| Ordinary shares, par value (in Dollars per share) | $0.00 | $0.00 | ||
| Ordinary shares, Authorized (in Shares) | 100.0M shares | 100.0M shares | ||
| Ordinary shares, Issued (in Shares) | 35.9M shares | 24.3M shares | ||
| Ordinary shares, Outstanding (in Shares) | 35.9M shares | 24.3M shares | 15.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$13.2M | -$11.1M | -$11.3M |
| Depreciation | $150.0K | $171.0K | $111.0K |
| Capital loss | $9.0K | $5.0K | $0 |
| Share based compensation expenses | $3.6M | $1.9M | $1.4M |
| Share based compensation placement agent warrants | $0 | $0 | $59.0K |
| Evaluation of financial liability at fair value | -$720.0K | $47.0K | -$306.0K |
| Expiration of financial liability | $0 | -$11.0K | $0 |
| Issuance cost | $0 | $0 | $205.0K |
| Issuance of ordinary shares - advisor fees | $116.0K | $62.0K | $0 |
| Prepayments of lease liabilities | $0 | -$9.0K | -$7.0K |
| Decrease (increase) in right of use assets, net | $99.0K | $31.0K | -$5.0K |
| Decrease (increase) in other current assets | $78.0K | -$84.0K | $190.0K |
| (Decrease) increase in trade accounts payables | -$47.0K | -$44.0K | $46.0K |
| (Decrease) increase in other accounts payable | -$58.0K | $118.0K | -$190.0K |
| (Increase) decrease in inventory | -$291.0K | -$444.0K | $0 |
| Unrealized foreign exchange (gain) loss | -$25.0K | -$55.0K | $65.0K |
| Financial expenses due to commitment fee Standby Equity Purchase Agreement (SEPA) | $250.0K | $0 | $0 |
| Issuance of ordinary shares - commitment fee (SEPA) | $223.0K | $0 | $0 |
| Net cash used in operating activities | -$9.9M | -$9.4M | -$9.7M |
| Purchase of property, plant, and equipment | -$103.0K | -$164.0K | -$206.0K |
| Change in deposits, net | $668.0K | $1.7M | $4.8M |
| Net cash provided by investing activities | $565.0K | $1.5M | $4.6M |
| Issuance of ordinary shares, pre-funded warrants and ordinary warrants, net | $1.8M | $7.9M | $3.4M |
| Exercise of options | $10.0K | $2.0K | $3.0K |
| Exercise of warrants and pre-funded warrants, net | $912.0K | $2.0K | $0 |
| Issuance of ordinary shares (issuances pursuant to an at-the-market facility), net | $4.6M | $0 | $26.0K |
| Net cash provided by financing activities | $7.3M | $7.9M | $3.5M |
| Effect of exchange rate changes on cash and cash equivalents | $25.0K | $55.0K | -$65.0K |
| Net increase (decrease) in cash and cash equivalents and restricted cash | -$2.0M | $16.0K | -$1.6M |
| Other receivable in connection to December private placement | $0 | $70.0K | $0 |
| Accrued issuance expenses | -$43.0K | -$220.0K | $0 |
| Financial liability- placement agent fee (Note 10-A) | $0 | -$69.0K | $0 |
| Share based compensation- placement agent warrants against additional paid in capital (Note 11) | $0 | -$254.0K | -$73.0K |
| Total non cash transactions | -$43.0K | -$473.0K | -$73.0K |
| Interest paid | $65.0K | $72.0K | $93.0K |
No quarter-by-quarter statement was filed.
Corporate structure
QTREX Quantum Ltd. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of QTREX Quantum Ltd.
- DAVIDSON KEMPNER CAPITAL MANAGEMENT LP Filed SCHEDULE 13G on QTREX Quantum Ltd., latest Aug 27, 2026
- Joe Ronen Hayon Filed SCHEDULE 13G/A on QTREX Quantum Ltd., latest Jul 13, 2026 (8 filings since Feb 17, 2022)
- ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G on QTREX Quantum Ltd., latest May 15, 2026 (3 filings since Feb 14, 2024)
- Dagi Shahar Ben-Noon Filed SCHEDULE 13G/A on QTREX Quantum Ltd., latest Mar 5, 2026 (4 filings since Feb 17, 2022)
- QTREX Quantum Ltd. L3
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What QTREX Quantum Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $972.0K2 Dec 31, 2025 | $869.0K2 Dec 31, 2024 | +11.9% |
| Accumulated depreciation | $520.0K2 Dec 31, 2025 | $370.0K2 Dec 31, 2024 | +40.5% |
| Property and equipment, net | $452.0K2 Dec 31, 2025 | $499.0K2 Dec 31, 2024 | −9.4% |
| Operating-lease assets (leased space) | $478.0K2 Dec 31, 2025 | $761.0K2 Dec 31, 2024 | −37.2% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $3.2M2 Dec 31, 2025 | $5.1M2 Dec 31, 2024 | −38.2% |
| Marketable securities, current | $700.0K2 Dec 31, 2024 | $2.3M8 Dec 31, 2023 | −69.6% |
Inventory
Leadership
Who has led QTREX Quantum Ltd., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
- Chief executive officerDagi Shahar Ben-Noon Mar 19, 2026 to now9
- Chief financial officerYafit Tehila Mar 19, 2026 to now10
- Chief operating officerAbraham Shabtay Mar 24, 2026 to now11
Board members and other officers (7)
- Chief Technology OfficerHayon Daniella Yechezkely Mar 19, 2026 to now12
- Chief Business OfficerYoav Rozanovich Apr 23, 2026 to now13
- Board memberDagi Shahar Ben-Noon Mar 19, 2026 to now9
- Board memberLior Amit Mar 19, 2026 to now14
- Board memberSivan Matza Mar 19, 2026 to now15
- Board memberTal Parnes Mar 19, 2026 to now16
- Board memberShlomit Chappel-Ram Jul 22, 2026 to now17
Named in SEC Form D filings
People the company listed in its private-offering notices.
- Chief Operations Officer and VP Research and DevelopmentAvi Shabtai named Jan 7, 202518
- Chief Technology OfficerDaniella Yehezkely Hayon named Jan 7, 202518
- President and DirectorJoe Hayon named Jan 7, 202518
- Chairman of the Board of DirectorsBenad Goldwasser named Jan 7, 202518
- DirectorLimor Rozen named Jan 7, 202518
Former names
- Inspira Technologies OXY B.H.N. LtdDec 29, 2020 to May 19, 20263
Timeline
- Mar 19, 2026New chief executive Dagi Shahar Ben-Noon becomes CEO9
Filings
339 filings to the SEC since October 2021: 7 annual reports, 26 insider forms, 16 large holders, 1 private raises, 289 other. The latest 20:
- Oct 15, 20264 EDGAR
- Oct 13, 20264 EDGAR
- Oct 9, 20266-K EDGAR
- Oct 9, 20264 EDGAR
- Oct 1, 20266-K EDGAR
- Sep 29, 20264 EDGAR
- Sep 29, 20264/A EDGAR
- Sep 24, 20266-K EDGAR
- Sep 2, 20266-K EDGAR
- Sep 1, 20264 EDGAR
- Sep 1, 20264 EDGAR
- Sep 1, 20264 EDGAR
- Sep 1, 20264 EDGAR
- Aug 28, 20266-K EDGAR
- Aug 27, 2026SCHEDULE 13G EDGAR
- Aug 21, 2026424B5 EDGAR
- Aug 20, 20266-K EDGAR
- Aug 19, 20266-K EDGAR
- Aug 3, 20266-K EDGAR
- Jul 31, 2026EFFECT EDGAR
The 339 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
6 open-market trades by officers, directors and large owners since October 2021: 1 buys and 5 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | Ben-Noon Dagi ShaharChief Executive Officer | Buy | 168,894 | $0.71 | $119.9K | Form 4 |
| Jun 1, 2026 | Tehila YafitChief Financial Officer | Sale | 28,100 | $3.50 | $98.3K | Form 4 |
| May 29, 2026 | Yechezkely Hayon DaniellaChief Technology Officer | Sale | 50,000 | $3.00 | $150.0K | Form 4 |
| May 29, 2026 | Tehila YafitChief Financial Officer | Sale | 1,900 | $3.51 | $6.7K | Form 4 |
| May 28, 2026 | Tehila YafitChief Financial Officer | Sale | 30,000 | $2.78 | $83.4K | Form 4 |
| May 27, 2026 | Tehila YafitChief Financial Officer | Sale | 30,000 | $2.02 | $60.6K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- DAVIDSON KEMPNER CAPITAL MANAGEMENT LPSCHEDULE 13G, 1 filing Aug 27, 202619
- Joe Ronen HayonSCHEDULE 13G/A, 8 filings Feb 17, 2022 to Jul 13, 202620
- ARMISTICE CAPITAL, LLCSCHEDULE 13G, 3 filings Feb 14, 2024 to May 15, 202621
- Dagi Shahar Ben-NoonSCHEDULE 13G/A, 4 filings Feb 17, 2022 to Mar 5, 202622
Money raised
Private offerings the company reported to the SEC on Form D.
- Dec 27, 2024Raised $8.3 million in a private offering of equity Form D: 12 investors so far Form D
SEC filer profile
How QTREX Quantum Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARQTREX Quantum Ltd.1
- CIK0001837493
- Filer statusNon-accelerated filer an emerging growth company; not a shell company4
- Incorporated inL34
- Fiscal year endsDecember 311
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business addressHatidhar 2, 11Th Floor, Ra'Anana, Israel1
- Phone972-9-96644881
- Shares outstanding35,949,247 shares as of Dec 31, 20254
- AuditorZiv Haft, Tel-Aviv, Israel PCAOB ID 1185; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceDec 29, 20201
- Filings387 in all: 6-K (216), 144 (18), CORRESP (17), 4 (16), EFFECT (13), UPLOAD (13), 424B5 (12), 3 (9)1
All 34 form types
F-1/A (8), SCHEDULE 13G/A (8), POS AM (7), S-8 (6), 20-F (5), F-1 (4), F-3 (4), FWP (4), SC 13G (3), SC 13G/A (3), 20-F/A (2), 424B4 (2), 6-K/A (2), CERT (2), SCHEDULE 13G (2), 25-NSE (1), 4/A (1), 424B3 (1), 8-A12B (1), 8-A12B/A (1), D (1), DRS (1), DRS/A (1), DRSLTR (1), F-1MEF (1), F-3/A (1)
- Latest filingsAnnual report (20-F) Mar 26, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Ordinary Shares, no par value | IINN | Nasdaq |
| Warrants to purchase Ordinary Shares | IINNW | Nasdaq |
From the cover page of the 20-F filed Mar 26, 2026 (Section 12(b) of the Exchange Act).4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARLior Amit, Board member
- 15SEC EDGARSivan Matza, Board member
- 16SEC EDGARTal Parnes, Board member
- 17SEC EDGARShlomit Chappel-Ram, Board member
- 18
- 19
- 20
- 21
- 22